Evidence map›Paper›PMID 35816690›Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2022

[COVID-19 mortality prediction. Comparison between two scales].

Alberto Arce-Zepeda, Armando Geovanni Araiza-Aguirre

Open access · greenAbstract read
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alberto Arce-ZepedaInstituto Mexicano del Seguro Social, Hospital General Regional No. 46, Coordinación Clínica de Educación e Investigación en Salud. Guadalajara, Jalisco, México.
Armando Geovanni Araiza-AguirreInstituto Mexicano del Seguro Social, Hospital General Regional No. 46, Área de Urgencias. Guadalajara, Jalisco, México.
Mexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prognosis and mortality in patients with COVID-19 are variable. The NEWS2 (National Early Warning Score) and REMS (Rapid Emergency Medicine Score) scales can be used quickly at hospital admission to predict mortality, no studies have been found that compare their predictive performance in our population. Objective: To compare NEWS2 and REMS to predict mortality in patients with COVID-19. Material and methods: Retrospective cohort with 361 patients. The variables were collected to calculate the NEWS2 and REMS scales and the reason for hospital discharge. The predictive value for mortality was analyzed using the ROC curve, establishing the area under the curve (AUC) with 95% confidence intervals (95% CI). The cut-off point (PC) with the best sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV), as well as relative risk (RR) with 95% CI. Results: The AUC of NEWS2 and REMS were 0.929 (95% CI: 0.903-0.956) and 0.913 (95% CI: 0.884-0.943), respectively. The PC of the NEWS2 scale was 8 points, with sensitivity 87.8% and specificity 82.1%, PPV 69.7% and NPV 93.5% and of the REMS scale of 7 points, with sensitivity 83.5% and specificity 83.7%, PPV 70.5% and NPV 91.6%. 8 or more points on the NEWS2 scale presenting a RR of 10.74 (95% CI: 6.4-18.03), and REMS 7 or more points RR 8.36 (95% CI: 5.36-13.02). Conclusion: Both tests presented good discriminative ability to predict mortality, being better according to AUC and RR in the NEWS2 scale.

Indexed as

COVID-19Hospital MortalityHumansRetrospective StudiesROC CurveSensitivity and SpecificityCoronavirus InfectionsEmergency MedicineHospital Mortality

Identifiers

PMID35816690
PMCPMC10395975
OpenAlexW4285078415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.